Emergent BioSolutions Inc. is a life sciences company that develops and provides solutions for public health threats, including biological, chemical, and radiological hazards. Its customers include government agencies, healthcare providers, and organizations involved in emergency preparedness. Revenue primarily comes from the sale of vaccines and therapeutics, with significant products including BioThrax (anthrax vaccine), ACAM2000 (smallpox vaccine), and NARCAN (opioid overdose treatment), contributing approximately 40%, 20%, and 15% of total revenue, respectively. The company also generates income from contract development and manufacturing services. Factors supporting its endurance include government contracts and a focus on public health, while reliance on government funding and regulatory approvals could limit growth potential.
—
Emergent BioSolutions Inc. is a life sciences company that develops and provides solutions for public health threats, including biological, chemical, and radiological hazards. Its customers include government agencies, healthcare providers, and organizations involved in emergency preparedness. Revenue primarily comes from the sale of vaccines and therapeutics, with significant products including BioThrax (anthrax vaccine), ACAM2000 (smallpox vaccine), and NARCAN (opioid overdose treatment), contributing approximately 40%, 20%, and 15% of total revenue, respectively. The company also generates income from contract development and manufacturing services. Factors supporting its endurance include government contracts and a focus on public health, while reliance on government funding and regulatory approvals could limit growth potential.
—
Daily adjusted close
Emergent BioSolutions Inc. is a life sciences company that develops and provides solutions for public health threats, including biological, chemical, and radiological hazards. Its customers include government agencies, healthcare providers, and organizations involved in emergency preparedness. Revenue primarily comes from the sale of vaccines and therapeutics, with significant products including BioThrax (anthrax vaccine), ACAM2000 (smallpox vaccine), and NARCAN (opioid overdose treatment), contributing approximately 40%, 20%, and 15% of total revenue, respectively. The company also generates income from contract development and manufacturing services. Factors supporting its endurance include government contracts and a focus on public health, while reliance on government funding and regulatory approvals could limit growth potential.